Latest News for: Vtv

Edit

Regulation FD Presentation (Form 8-K) (vTv Therapeutics Inc)

Public Technologies 31 Mar 2025
). The text version of this document is not available ... vTv Therapeutics Inc.
Edit

VTV, Kia Horse shake hands to push talents of arts

Vietnam News 22 Mar 2025
The Việt Nam Television (VTV) and ... Secretary of the VTV's Youth Union Phùng Văn Hiệp said ... Therefore, the signing ceremony is very important for the works of VTV in general and VTV youth in particular".
Edit

VTv Therapeutics: Q4 Earnings Snapshot

Reflector 21 Mar 2025
HIGH POINT, N.C. (AP) — HIGH POINT, N.C. (AP) — VTv Therapeutics Inc. (VTVT) on Thursday reported a loss of $3.6 million in its fourth quarter ... .
Edit

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update (Form 8-K) (vTv Therapeutics Inc)

Public Technologies 20 Mar 2025
) vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update ... HIGH POINT, N.C., March 20, 2025 - vTv Therapeutics Inc ... He has also served as a consultant of vTv Therapeutics since 2023.
Edit

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K) (vTv Therapeutics Inc)

Public Technologies 20 Mar 2025
vTv Therapeutics Inc. is a holding company and its principal asset is a controlling equity interest in vTv Therapeutics LLC ("vTv LLC"), the principal operating subsidiary ... vTv Therapeutics Inc ... Net loss attributable to vTv Therapeutics Inc.
Edit

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes (Form 8-K) (vTv Therapeutics Inc)

Public Technologies 17 Mar 2025
) vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes ... HIGH POINT, N.C., March 17, 2025 - vTv Therapeutics Inc ... About vTv Therapeutics. vTv Therapeutics Inc ... vTv Therapeutics Inc.
Edit

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Nasdaq Globe Newswire 17 Mar 2025
Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes ... .
  • 1
×